| A controlled Type 2 diabetic applying for ₹1 crore term cover in 2026 will pay between ₹19,000 and ₹38,000 a year, or get declined. The single number that decides almost everything sits on one line of one lab report. |
The Short Version (2-Minute Read)
1. Diabetes is not a disqualification. Almost every major Indian life insurer issues term policies to controlled Type 2 diabetics in 2026. The agent or relationship manager who tells you otherwise is uninformed or selling you something else, usually a ULIP.
2. HbA1c decides almost everything. Below 5.7% is non-diabetic. 5.7 to 6.4 is pre-diabetic. 6.5 to 7 attracts a 25 to 50 percent loading at most insurers. 7 to 8 attracts 75 to 100. Above 8.5, most insurers postpone or decline.
3. There is exactly one diabetic-specific term plan in India. Bajaj Life Diabetic Term Plan II Sub 8 HbA1c, eligible for HbA1c at or below 8 percent, with a 10 percent annual "Keep Fit" premium reduction if your readings improve. Useful in the 7.5 to 8 band; usually overpriced for cleaner profiles.
4. The September 2025 GST exemption matters more for diabetics. Individual life insurance premiums went from 18 percent GST to nil with effect from 22 September 2025. On a loaded diabetic premium of ₹35,000 a year, that is ₹6,300 saved each year, roughly ₹1.9 lakh over a 30-year policy.
5. Section 45 of the Insurance Act 1938 is your strongest protection. After three years from issuance, the insurer cannot question the policy except on proven fraud. Honest disclosure on the proposal form and the Diabetes Mellitus Questionnaire is what makes that protection actually work.
The full HbA1c band table, insurer-by-insurer matrix, real rupee math on a ₹1 crore policy, and the Critical Illness rider trap most diabetic buyers fall into, below.
By Dinesh Kumar S · Published May 4, 2026 · 16 min read
Last verified against IRDAI Master Circular on Life Insurance Products dated 12 June 2024, IRDAI Master Circular on Protection of Policyholders' Interests dated 5 September 2024, CBIC Notification No. 16/2025 dated 17 September 2025, and Bajaj Life Diabetic Term Plan II Sub 8 HbA1c product literature, on 2 May 2026.
Last September I got an email from Dr. Meena Joshi, a microbiology professor in Pune who had been diagnosed with Type 2 diabetes three weeks earlier. Her HbA1c had come back at 7.4 percent on the first reading. Her endocrinologist had started her on Metformin 500mg twice daily. Her relationship manager at the bank had used a Friday afternoon meeting in his cubicle in Aundh to tell her, in a confident tone, that no Indian life insurer would now issue her a term policy and she should consider a ULIP from the bank's life insurance arm instead. She has two school-age children, an existing home loan in her name, and a husband whose income would not cover both the EMI and the household if anything happened to her. The relationship manager's "no insurer will take you" had landed badly enough that she had not slept properly that weekend. Her email asked, very politely, whether the relationship manager was correct or whether he was selling her something.
He was selling her something. Her HbA1c puts her in a band that every meaningful private insurer issues policies in. The premium loading is real but predictable, and the rupee gap between her cover and what a non-diabetic of the same age pays is smaller than the gap between buying that ULIP and not buying it. The relationship manager either did not know what current diabetic underwriting in India looks like, or he did know and was hoping she did not.
This article is the answer I sent her, expanded into the full picture. Eight years of reader emails on the same theme has made me convinced that diabetic underwriting is the single most consistently mis-sold corner of Indian life insurance, and that almost every diabetic reader who arrives at my inbox has been told some variation of "you cannot get a term policy" by an agent or banker who has not bothered to check what is actually on offer in 2026. The article walks through the HbA1c bands that decide everything, the insurer-by-insurer position, the only diabetic-specific term plan in the Indian market, the rupee math on a ₹1 crore policy across 30 years, the Critical Illness rider trap most articles miss, the legal protection under Section 45 of the Insurance Act 1938 that diabetics need most, and the practical playbook to follow before you submit a proposal. The aim is to leave you knowing more about diabetic underwriting than the agent sitting across the desk.
In This Article
▸ HbA1c — The Single Number That Decides Everything
▸ Which Insurers Accept Diabetics in 2026 — The Honest Matrix
▸ The Only Diabetic-Specific Term Plan in the Indian Market
▸ The Real Rupee Math on a ₹1 Crore Policy
▸ Disclosure and Section 45 — The Three-Year Shield
▸ The Critical Illness Rider Trap Most Diabetic Buyers Fall Into
▸ What to Do If You Are Declined or Loaded Heavily
▸ A Practical Playbook Before You Apply
HbA1c — The Single Number That Decides Everything
The HbA1c reading from your most recent lab report is the number on which the underwriter's decision turns. Fasting blood glucose tells you what you ate yesterday. HbA1c, technically glycated haemoglobin, captures average blood glucose over the previous eight to twelve weeks, which is a far better proxy for how the underlying disease has actually been controlled. Indian insurers borrow their bands from the WHO and ICMR diagnostic thresholds. Below 5.7 percent is non-diabetic. 5.7 to 6.4 is pre-diabetic. 6.5 and above is diabetic. For underwriting purposes, well-controlled sits below 7 percent. Moderately controlled runs from 7 to 8.5. Above 8.5 most insurers postpone, ask for a retest in three months, or decline outright.
The table below shows the broad loading ranges that the major Indian insurers apply to a 35-year-old male non-smoker applying for ₹1 crore sum assured over a 30-year term. I want to be upfront about where these numbers come from. No Indian insurer publishes its Board-Approved Underwriting Policy. The bands here are reconstructed from publicly available insurer brochures that include illustrative diabetic loadings, broker case data from Ditto Insurance and Beshak, the Outlook Money and Business Standard reporting on the Bajaj diabetic plan launch, and a small number of insurer consumer guides that publish HbA1c-band guidance. These ranges are indicative, not guaranteed. Your actual quote depends on the specific insurer's then-current underwriting view, your full medical profile including BMI, BP and lipid panel, and the outcome of pre-policy medical tests.
| HbA1c Band | Clinical Profile | Indicative Loading | Likely Outcome |
| Below 5.7% | Non-diabetic, normal markers | 0% | Standard issue |
| 5.7 to 6.4% | Pre-diabetic, no medication, normal BMI/BP/lipids | 0 to 25% | Almost always issued |
| 6.5 to 7% | Type 2, controlled, oral meds only, no complications | 25 to 50% | Routinely issued |
| 7 to 8% | Type 2, moderately controlled | 75 to 100% | Frequently issued, sometimes postponed for retest |
| 8 to 8.5% | Type 2, longer duration or higher reading | 100 to 150% | Issued with heavy loading or postponed |
| 8.5 to 10% | Poorly controlled or with mild complications | 150% or more | Often declined; if accepted, smaller sum assured |
| Above 10% or with major complications | Retinopathy, nephropathy, IHD, stroke, CKD stage 3+ | Decline in most cases | Group cover or alternatives |
| Type 1 diabetes | Insulin-dependent, generally early onset | Rare retail acceptance | Group cover via employer is usually the only path |
Two practical points follow that most articles miss. The difference between the 25 percent loading band and the 100 percent loading band is often a single twelve-week stretch of disciplined glycaemic control. A reader whose last reading was 8.4 but who has stuck strictly to diet, exercise and medication for three months may retest at 7.0 or 7.2, shift one full band, and save roughly 3 to 6 lakh in cumulative premiums on a 30-year ₹1 crore policy. I have followed two reader cases in 2024 and 2025 where exactly this happened. The other point: age compounds the HbA1c effect rather than substituting for it. A 45-year-old at HbA1c 7.0 will face heavier loading than a 35-year-old at the same reading, because mortality risk multiplies on the age curve at every diabetic band.
| Six bands. Each one represents a different insurer reaction. The cumulative cost gap between band 3 and band 5 over thirty years on a ₹1 crore policy runs into roughly ₹4 to ₹5 lakh of extra premium for the same cover. |
Which Insurers Accept Diabetics in 2026 — The Honest Matrix
No single published table of "which insurer accepts which diabetic profile at what loading" exists in India. What follows is reconstructed from public brochures, broker case studies, and insurer consumer guides as of April 2026. Treat it as indicative for shortlisting, not as a guarantee for any individual case.
| Insurer (IRDAI Reg. No.) | Flagship Term Plan | Diabetic Underwriting Stance |
| HDFC Life (101) | Click 2 Protect Super (UIN 101N145V02), Click 2 Protect Supreme (UIN 101N183V01) | Accepts well-controlled Type 2; thorough medicals expected; loadings of 25 to 75 percent typical for HbA1c under 7.5; consistently strong claim settlement record at 99.7 percent in FY24-25 |
| ICICI Prudential Life (105) | iProtect Smart Plus | Generally favourable view of stable Type 2 diabetics; accepts well-controlled cases with reasonable loading |
| Axis Max Life (104) | Smart Term Plan Plus, Smart Secure Plus | Among the more flexible underwriters when HbA1c, BP and BMI are stable; the inbuilt waiver-of-premium-on-disability option is particularly valuable for diabetics |
| Tata AIA Life (110) | Sampoorna Raksha Promise, Maha Raksha Supreme Select | Accepts controlled Type 2; consumer guides explicitly distinguish HbA1c under 6.5 from 6.5 and above; competitive base premiums |
| Bajaj Life (116) (formerly Bajaj Allianz Life) | eTouch II and Diabetic Term Plan II Sub 8 HbA1c | Only diabetic-specific term product currently on the market in India. Designed for Type 2 with HbA1c at or below 8 and pre-diabetics. Includes a "Keep Fit" benefit reducing premium by 10 percent on each policy anniversary if HbA1c improves. Detailed in the next section. |
| Aditya Birla Sun Life (109) | DigiShield Plan | Brochure explicitly notes extra premium may be charged for substandard lives. The ABSLI Activ Diabetes plan is health insurance only, not term, despite the similar name |
| LIC of India (512) | New Tech Term, New Jeevan Amar, Digi Term, Bima Kavach | Accepts diabetics but is conservative; loadings are typically similar to private peers despite the persistent myth of "only LIC takes diabetics"; underwriting tables are not public; agent-led negotiation common |
| Bandhan Life (formerly Aegon) | iTerm range | Accepts controlled Type 2; underwriting similar to private peers; rebranded after the 2023 acquisition |
| Canara HSBC Life | iSelect Smart360 Term | Accepts well-controlled Type 2; consumer benchmarks of HbA1c at or below 7.5 published as favourable; bank-led distribution helps |
| SBI Life (111) | eShield Next | Accepts controlled Type 2; underwriting historically moderate; widely used as a benchmark in diabetic comparisons |
| Kotak Life (107) | e-Term Plus | Accepts controlled Type 2; competitive premiums for clean profiles; loading practice varies case to case |
The single most useful takeaway from this matrix is that almost every meaningful Indian life insurer issues term cover to a controlled Type 2 diabetic in 2026. The differentiation lies in the loading band, the speed of underwriting, the quality of the empanelled diagnostic centres in your city, and the claim settlement record at the eventual end of the policy. For most readers, the practical winner is the insurer whose claim settlement ratio is consistently above 99 percent, whose medical underwriting is fair on the loading, and whose product structure includes a meaningful waiver-of-premium-on-disability rider. Among the major insurers, that combination usually points to HDFC Life, Axis Max Life, ICICI Prudential and Tata AIA in the private space, and LIC for buyers who specifically prefer the public sector option for emotional reasons. Bajaj's diabetic-specific plan is its own conversation, which is the next section.
The Only Diabetic-Specific Term Plan in the Indian Market
Bajaj Life Diabetic Term Plan II Sub 8 HbA1c (the company is now Bajaj Life Insurance Limited, rebranded from Bajaj Allianz Life, IRDAI Reg. No. 116) is the only dedicated diabetic term insurance product available retail in India in 2026. It is worth understanding in detail because it is the only plan designed from the ground up for a diabetic underwriting profile, and the design choices it makes shed light on how every other insurer thinks about the same risk under the hood.
The product accepts entry ages from 30 to 60 years, with policy terms running from 5 to 25 years and premium-paying term equal to policy term. Sum assured starts at ₹25 lakh with no upper limit. Eligibility is a current HbA1c reading at or below 8 percent, which captures pre-diabetics and Type 2 diabetics in the controlled to moderately controlled bands. Type 1 diabetes is not eligible. The plan is pure-risk only, with no maturity benefit or surrender value. Premium is determined by age, gender, smoker status, sum assured, current HbA1c level, policy term and frequency of payment.
The most distinctive feature is the "Keep Fit" benefit. On every policy anniversary, if your HbA1c reading has improved against the previous year, you receive a 10 percent reduction on the next year's premium. The discount applies to base premium, not riders or taxes, and it is applied year by year rather than compounded across years. Over a 25-year term a diligent diabetic policyholder who maintains tight glycaemic control can recover a meaningful portion of the upfront loading penalty through this mechanism. No other Indian insurer offers an equivalent dynamic-loading feature on a term product as of April 2026.
Bajaj also offers Health Management Services to active policyholders: an annual HbA1c test, medical second opinion, medical case management, vitals tracking, periodic webinars on diabetes management. Whether you actually use these services depends on you. They do not replace your treating endocrinologist; they are a layer of free engagement that some readers find useful and others ignore.
The trade-off is price. Bajaj's diabetic-specific plan is priced roughly 50 to 100 percent above what the same applicant would pay for a mainstream term plan from any major private insurer at a 25 to 50 percent loading. Bajaj's own product literature illustrates a 35-year-old male non-smoker with ₹1 crore cover over a 20-year term at an annual premium of around ₹26,838 inclusive of GST under the pre-September 2025 regime. Post-September 2025 GST exemption, the same premium drops to roughly ₹22,700. A mainstream Click 2 Protect Super or iProtect Smart Plus for the same applicant at HbA1c 6.8 with a 25 percent loading would land closer to ₹19,000 to ₹23,000 a year. The dedicated product makes most sense for diabetics whose HbA1c sits in the 7.5 to 8 range, where mainstream insurers may load very heavily or postpone, and where the simplified eligibility of the Bajaj plan becomes a real advantage. For controlled diabetics under HbA1c 7, a mainstream term plan with a moderate loading is usually the cheaper choice.
One specific limitation worth knowing. The Bajaj plan does not currently offer a Critical Illness rider or a structured Limited Pay option. If those features matter to you, you will need to source them through the base mainstream plan you are also being quoted, which means running both quotes in parallel before deciding.
The Real Rupee Math on a ₹1 Crore Policy
Loading percentages are useful for comparison but rupee numbers are what actually drive the buying decision. Take a 35-year-old male non-smoker, applying for ₹1 crore term cover over 30 years, in May 2026, with the September 2025 GST exemption now in force on individual life premiums. The non-diabetic baseline annual premium across major private insurers sits between ₹13,000 and ₹17,000. HDFC Life Click 2 Protect Supreme illustrative example for a 35-year-old male over 40 years lands at ₹20,892 annually excluding taxes (and now post-exemption, that excluded-taxes figure is the actual figure). Layering the diabetic loading bands onto this kind of baseline produces the table below, which is the closest a publicly available source can get to the quote you will actually receive.
| Profile (35-year-old male, ₹1 cr, 30 years) | Indicative Loading | Annual Premium (₹) | 30-Year Total (₹) |
| Non-diabetic baseline | 0% | 13,000 to 17,000 | 3.9 to 5.1 lakh |
| Pre-diabetic, HbA1c 5.7 to 6.4 | 0 to 25% | 13,000 to 21,000 | 3.9 to 6.3 lakh |
| Type 2 controlled, HbA1c 6.5 to 7 | 25 to 50% | 17,000 to 25,000 | 5.1 to 7.5 lakh |
| Type 2 moderate, HbA1c 7 to 8 | 75 to 100% | 23,000 to 34,000 | 6.9 to 10.2 lakh |
| Type 2 elevated, HbA1c 8 to 8.5 | 100 to 150% | 28,000 to 42,000 | 8.4 to 12.6 lakh |
| Type 2 with one early complication | 150% or decline | 35,000+ or no offer | 10.5 lakh+ or no policy |
| Bajaj Diabetic Term Plan II (20-year term illustrative) | Built-in diabetic pricing | 22,700 to 38,000 | 4.5 to 7.6 lakh (20-year max) |
Three observations on the rupee math that are worth dwelling on. The cumulative cost of moving from a 25 percent loading band to a 100 percent loading band over 30 years is roughly ₹2.7 to ₹3 lakh of additional premium, which is more than a comprehensive multi-year health insurance policy or a small four-wheeler down payment. The cumulative cost of being declined at retail and forced into either group cover only or a high-loaded specialty plan is roughly ₹4 to ₹5 lakh in additional premium versus what a controlled diabetic at HbA1c 6.8 would pay in a mainstream policy. And the September 2025 GST exemption alone has saved every individual term policyholder roughly 15 percent on every annual premium going forward, which compounds to around ₹1.9 to ₹2 lakh of saved tax over a 30-year ₹1 crore policy.
The exemption is worth a small footnote of its own because the timing rules trip up policyholders who pay around the cutover date. The CBIC notification 16/2025 dated 17 September 2025 (effective 22 September 2025) tied the rate change to the time of supply under Section 13 of the CGST Act 2017. If the premium invoice or payment date is on or after 22 September 2025, GST is nil. If it falls before, the old 18 percent applies. There is no retrospective refund. Group term policies and most riders on group policies still attract 18 percent GST, so the exemption preserves a real cost advantage of individual term cover over employer-routed alternatives where you can qualify for both.
Disclosure and Section 45 — The Three-Year Shield
Of all the legal provisions in Indian life insurance, Section 45 of the Insurance Act 1938 is the one that matters most to a diabetic policyholder. Section 45, as substituted by the Insurance Laws (Amendment) Act 2015 and operative in its current form for over a decade, says that no life insurance policy can be called into question by the insurer after three years from the date of issuance, the date of commencement of risk, the date of revival, or the date of any rider, whichever is later. Within this three-year contestability window, the insurer can repudiate a claim on grounds of misstatement or non-disclosure of material facts. After three years, the insurer can repudiate only on grounds of proven fraud, with the burden of proof resting squarely on the insurer.
For a diabetic, this is the single most powerful protection in the system. Diabetes is a "material fact" that affects underwriting, and inside the contestability window an insurer can and frequently does repudiate claims where diabetes was undisclosed or partially disclosed at proposal. After three years, with full disclosure on file, the policy becomes very hard to dislodge.
The Supreme Court's 10 April 2024 ruling in Mahakali Sujatha v. The Branch Manager, Future Generali India Life Insurance Co. Ltd. & Anr. (Civil Appeal No. 3821 of 2024, neutral citation 2024 INSC 296, also reported as (2024) 8 SCC 712) is the most useful recent precedent on this point. The case itself was about non-disclosure of other existing insurance policies, not about diabetes specifically, so I want to be honest about its scope. The principle the two-judge bench of Justices B.V. Nagarathna and Augustine George Masih established applies broadly to any non-disclosure dispute. The burden of proving both the alleged non-disclosure and any fraudulent intent rests on the insurer. Ambiguities in the proposal form are read against the insurer under the doctrine of contra proferentem. For a diabetic policyholder whose policy crosses the three-year window, this ruling significantly weakens the standard insurer playbook of citing minor proposal-form omissions to justify repudiation.
The practical consequence is that complete and honest disclosure at proposal is the cheapest insurance against future claim repudiation. The cost of disclosure is a higher upfront loading. The cost of non-disclosure is a potential repudiation in the first three years, followed by a long and expensive escalation through the insurer's grievance officer, the Bima Bharosa portal, the Insurance Ombudsman, and possibly the consumer commissions. For readers facing such a dispute, the full escalation path is set out in the companion guide on how to file a complaint against an insurance company.
What complete disclosure actually looks like, in practice, is filling the Diabetes Mellitus Questionnaire (DMQ) honestly. Most insurers ask the applicant or treating physician to complete this form covering date of diagnosis, all current and past medications with doses, frequency of physician follow-up, history of any episode of diabetic ketoacidosis or severe hypoglycaemia, and a complications screen across eyes, kidneys, nerves and cardiovascular system. The DMQ is part of the proposal under Section 45. False or partial answers are the most common ground for claim repudiation in diabetic cases at the NCDRC level. Disclosing accurately costs you nothing beyond a higher upfront loading. It buys you the three-year shield that genuinely protects your family.
One more disclosure point: prior insurance applications and any prior decline must be disclosed. Indian insurers exchange application data through the Insurance Information Bureau of India database. A previously declined applicant who applies fresh to a new insurer without disclosing the earlier decline is committing exactly the kind of non-disclosure Section 45 is designed to catch within the first three years. Disclose the decline along with the reason given, attach the correspondence, and let the new insurer take a fresh underwriting view. A different insurer often takes a different view of the same medical profile.
The Critical Illness Rider Trap Most Diabetic Buyers Fall Into
Almost every guide on diabetic term insurance recommends adding a Critical Illness rider, on the reasonable-sounding logic that diabetics carry higher long-term risk of cancer, kidney failure, heart attack and stroke, all of which feature on the standard CI rider list of 30 to 60 conditions. The advice sounds sensible. It is also wrong in a way that costs diabetic policyholders meaningful money in premium for cover that may never pay out, and this is the most under-reported nuance in the entire diabetic life insurance topic in India.
The mechanics of a CI rider are straightforward. You add it at policy inception with a separate sum assured (usually 25 to 100 percent of the base term cover, capped per insurer rules), you pay an additional annual premium, and on diagnosis of a covered condition (after a survival period of typically 14 to 30 days) the rider pays out a lump sum independent of the death benefit. The rider terminates after payout. The base term cover continues. So far so good.
The trap for diabetics sits in three layers of fine print most insurer marketing material does not foreground. The first is the pre-existing disease exclusion. Almost every CI rider in the Indian market contains a clause excluding claims arising directly or indirectly out of a pre-existing disease that was disclosed or should have been disclosed at proposal. Diabetes, once disclosed, becomes a pre-existing disease for rider purposes. Chronic kidney disease arising from diabetic nephropathy is therefore typically excluded. So is ischaemic heart disease where atherosclerosis is attributed to long-standing diabetes. Stroke where the underlying cause is uncontrolled diabetes is on shaky ground. Diabetic retinopathy is not on the listed conditions of most riders in the first place. The conditions diabetics are statistically most likely to face in their fifties and sixties are precisely the conditions the rider is most likely to exclude as PED-related.
The second layer is the strict medical definition of each listed condition. "Chronic kidney disease requiring dialysis" pays only when dialysis or transplantation is initiated, not when the policyholder is at stage 3 or stage 4 CKD on conservative management. "Cancer of specified severity" excludes early-stage carcinoma in situ in most rider wordings. "Major organ transplant" requires the procedure to actually be performed. The thresholds are set high to keep premiums affordable for the rider as a whole, which is fine in the aggregate, but for a diabetic with progressive complications the gap between clinical disease and rider-triggering severity can be the difference between meaningful financial protection and none.
The third layer is the survival period. Most riders require the policyholder to survive 14 to 30 days from the date of diagnosis before payout. Diabetic complications often present acutely, particularly cardiac events. A diabetic who suffers a fatal heart attack on day 8 after diagnosis triggers the death benefit on the base term cover (which the family receives) but the CI rider lapses without payout.
| The conditions diabetics are most likely to face in their fifties and sixties are precisely the conditions a Critical Illness rider is most likely to exclude as arising from a pre-existing disease. Read the rider wording before paying for it. |
The honest verdict on CI riders for diabetics: they retain real value against cancer, where the underlying mechanism is independent of diabetes, and against the small subset of listed conditions unlikely to be characterised as diabetic complications. They are not a substitute for a comprehensive senior citizen health insurance policy or a critical-illness-only standalone health policy that may have more favourable diabetic-specific terms. Reader complaints to the Insurance Ombudsman in 2023, 2024 and 2025 have repeatedly involved CI rider claims rejected on PED grounds in diabetic cases, and the Ombudsman's awards have generally upheld the insurer's position when the exclusion is clearly worded. Read the rider wording yourself before paying for it. If the wording is ambiguous, ask the insurer in writing whether complications attributable to diabetes are covered. Keep the answer.
What to Do If You Are Declined or Loaded Heavily
A retail decline is not the end of the road, but the alternatives need a clear-eyed view of what each provides and what it does not.
Group term insurance through your employer is the strongest fallback for almost every diabetic of working age. Most large Indian employers carry a group policy with one of the major insurers, typically two to five times annual cost-to-company, issued under simplified or no underwriting up to a free cover limit. Diabetics with HbA1c well above retail thresholds routinely receive full group cover. Two catches. Cover ceases on exit from employment, and most insurers permit conversion to an individual policy without fresh medicals only if initiated within 30 days of leaving service, with the converted policy priced at retail rates with full underwriting applied at conversion. Group policies still attract 18 percent GST after the September 2025 reform, unlike individual policies which are now exempt, so the cost gap between group and individual cover for a healthy applicant is now visible.
Postal Life Insurance and Rural Postal Life Insurance, run by India Post under a statutory exemption from the Insurance Act 1938, are an underused option. Eligibility is restricted to specific occupational categories: central and state government employees, defence and paramilitary, public sector undertakings, employees of nationalised and scheduled commercial banks, recognised educational institutions, and certain professionals (doctors, engineers, chartered accountants, advocates, architects). For non-medical-scheme PLI policies up to ₹5 lakh under age 40, the medical examination is waived, which can be a real advantage for diabetics whose HbA1c would attract a heavy loading at private insurers. Higher sum assured PLI policies do require medical underwriting and treat diabetes much like private insurers.
Smaller sum assured policies, where insurers waive medical tests for sums assured of ₹25 to ₹50 lakh under age 40 with a satisfactory health declaration, are sometimes used by diabetics who have been declined for higher cover. Cost per ₹ of cover is higher, the disclosure obligation remains as strict, and any prior decline must be disclosed in the new application. Splitting required cover across two or three smaller policies from different insurers is sometimes suggested but is legally fraught. Indian insurers exchange application data through the IIB database, and coordinated declines are common.
A short note on a few smaller options I get asked about. Saral Jeevan Bima, the IRDAI-mandated standardised pure term product offered by every life insurer, has uniform terms across the industry; underwriting still applies, but for clean Type 2 profiles the issue rates are reportedly more favourable than for premium products. Pradhan Mantri Jeevan Jyoti Bima Yojana provides ₹2 lakh life cover for ₹436 a year via savings bank account self-declaration; useful as a layer, not a substitute. Home Loan Protection Plans alongside home loan disbursement use lighter underwriting because the cover is tied to the loan balance, but the cover decreases as the loan amortises and disappears when the loan is repaid.
A Practical Playbook Before You Apply
Five things to do before submitting a proposal.
One. Spend three months tightening glycaemic control and then retest within two weeks of submitting the proposal. The HbA1c reading reflects average blood glucose over the previous eight to twelve weeks, so a focused window of dietary discipline, medication compliance and physical activity translates directly into a lower reading at retest. The financial leverage is substantial. Moving from HbA1c 8.4 to 7.0 can shift you from a 100 percent loading band to a 25 to 50 percent band, saving roughly ₹3 to ₹6 lakh in cumulative premiums on a ₹1 crore 30-year policy.
Two. Disclose accurately and completely on the proposal form and the Diabetes Mellitus Questionnaire. Date of diagnosis, all current and past medications with doses, frequency of physician follow-up, complications screening done in the last year, prior insurance applications and any prior declines. The cost of disclosure is a one-time loading. The cost of non-disclosure is potential repudiation under Section 45 within the first three years.
Three. Work with one well-matched insurer at a time rather than applying simultaneously to multiple. Use a fee-based independent broker like Ditto Insurance or Beshak to pre-screen against likely underwriting acceptance before you formally apply. Multiple simultaneous applications often result in coordinated declines because insurers see each other's data through the IIB.
Four. Obtain a treating physician's letter on letterhead, dated within the last 60 days, confirming current diagnosis, medications with doses, frequency of follow-up, glycaemic control trend, and the absence of complications on annual screening. This single document materially helps in borderline underwriting decisions and can shift a quote by one band. Cost: a single consultation.
Five. Look hard at the riders being recommended. Waiver of premium on disability is genuinely valuable for diabetics given the elevated risk of complications affecting earning capacity, and it is typically inexpensive. Accidental death benefit is health-blind in most cases and is a reasonable add-on. Critical Illness, as the previous section laid out, requires reading the specific exclusion wording before paying for it. The companion guide on how to increase sum assured in an existing term plan without a fresh medical test covers the life-stage benefit options that can be useful alongside an initial diabetic policy as your circumstances change. For the rules that decide what a nominee actually receives at claim time, including the beneficial-versus-custodial distinction under Section 39(7), see the related piece on term insurance nominee rules after death of nominee.
Dr. Joshi got her policy in November. HDFC Life Click 2 Protect Super, ₹1 crore cover, 30-year term, with a 50 percent loading on her HbA1c 7.4 reading. The premium worked out to ₹24,200 for the first year. She had retested in late October and her reading had dropped to 7.1, which kept her in the same band but at the lower end of it. She wrote to me in February to say her relationship manager at the bank had stopped suggesting the ULIP after she politely informed him that her term policy was issued and active. She asked one more question, on which she had spent some time thinking. If the agent had been so confidently wrong about something this central to his job, what else had he been wrong about. The honest answer to that question is long and is for another article. The short answer is that the same agent who tells a controlled diabetic she cannot buy term insurance has often been telling clean applicants the same thing for years, just with different products replacing the term plan in the recommendation. The remedy is the same in both cases. Read the wording. Verify the underwriting. Disclose honestly. Buy the cover before you need it.
Sources and References
▸ Insurance Act, 1938 — Section 45 as substituted by the Insurance Laws (Amendment) Act, 2015
▸ IRDAI (Insurance Products) Regulations, 2024
▸ IRDAI (Protection of Policyholders' Interests, Operations and Allied Matters of Insurers) Regulations, 2024
▸ IRDAI Master Circular on Life Insurance Products — Ref. IRDAI/ACTL/MSTCIR/MISC/89/6/2024 dated 12 June 2024
▸ IRDAI Master Circular on Protection of Policyholders' Interests — Ref. IRDAI/PP&GR/CIR/MISC/117/9/2024 dated 5 September 2024
▸ Income-tax Act, 1961 — Section 10(10D) on tax exemption of term insurance death benefit; Section 80C(2)(xi)
▸ Mahakali Sujatha v. The Branch Manager, Future Generali India Life Insurance Co. Ltd. & Anr., Civil Appeal No. 3821 of 2024, 2024 INSC 296, (2024) 8 SCC 712, decided 10 April 2024
▸ Reliance Life Insurance Co. Ltd. v. Rekhaben Nareshbhai Rathod, (2019) 6 SCC 175
▸ LIC of India v. Smt. Asha Goel, (2001) 2 SCC 160
▸ Satwant Kaur Sandhu v. New India Assurance Co., (2009) 8 SCC 316
▸ GST Council 56th Meeting Recommendations dated 3 September 2025 on individual life and health insurance exemption
▸ CBIC Notification No. 16/2025-Central Tax (Rate) dated 17 September 2025, effective 22 September 2025
▸ Bajaj Life Diabetic Term Plan II Sub 8 HbA1c product brochure and sales literature at bajajlifeinsurance.com
▸ Bajaj Life eTouch II product brochure at bajajlifeinsurance.com
▸ HDFC Life Click 2 Protect Super (UIN 101N145V02) product brochure at hdfclife.com
▸ HDFC Life Click 2 Protect Supreme (UIN 101N183V01) product brochure at hdfclife.com
▸ Tata AIA Sampoorna Raksha Promise and Maha Raksha Supreme Select product brochures at tataaia.com
▸ ICICI Prudential iProtect Smart Plus product literature at iciciprulife.com
▸ Axis Max Life Smart Term Plan Plus and Smart Secure Plus product brochures at axismaxlife.com
▸ LIC of India product information for New Tech Term, New Jeevan Amar, Digi Term and Bima Kavach at licindia.in
▸ Aditya Birla Sun Life DigiShield Plan brochure at adityabirlasunlifeinsurance.com
▸ Postal Life Insurance and Rural PLI scheme details at pli.indiapost.gov.in
▸ Pradhan Mantri Jeevan Jyoti Bima Yojana scheme details at jansuraksha.gov.in
▸ World Health Organization classification and ICMR-INDIAB diagnostic thresholds for HbA1c in diabetes and pre-diabetes
▸ Insurance Information Bureau of India database guidance on insurer data exchange
▸ Ditto Insurance — diabetic term insurance case data and underwriting guidance at joinditto.in
▸ Beshak — independent insurance research and HDFC Life / Bajaj Life diabetic term insurance product comparisons at beshak.org
▸ Outlook Money and Business Standard reporting on the Bajaj Allianz Life Diabetic Term Plan launch, 2022 and 2023
Disclaimer: This article is for educational purposes only and does not constitute insurance advice, financial advice, or a recommendation to buy any specific product. Premium ranges, loading bands and insurer-specific positions are illustrative and based on publicly available brochures, broker case data and regulatory filings as of April 2026; actual quotes vary by individual medical profile, the insurer's then-current underwriting policy and the date of application. Dr. Meena Joshi is a real reader; her name and identifying details have been changed at her request. Finance Guided is not a SEBI-registered investment advisor, IRDAI-licensed insurance broker, AMFI-registered mutual fund distributor, or Chartered Accountant, and does not earn commission or referral fee from any insurance company named in this article. Always read the policy wording carefully, obtain personalised quotes directly from licensed insurers or fee-based advisors, and verify all product features, exclusions and current premium quotations before making a purchase decision.
Dinesh Kumar S
Founder & Author — Finance Guided
B.Sc. Mathematics | M.Sc. Information Technology | Chennai, Tamil Nadu
Dinesh started Finance Guided because most insurance, tax and personal finance content in India is written for professionals, not for the salaried families and young IT workers who actually have to make the decisions. He writes research-based guides verified against IRDAI, SEBI, RBI, EPFO and Income Tax Department sources. No product sales. No commissions. No paid placements.
0 Comments